Cyclic bisphosphonate therapy in osteogenesis imperfecta type V

Journal of Paediatrics and Child Health

Volumn 41, Issue 3, 2005, Pages 147-151

  Fleming, F ^a   Woodhead, H J ^a   Briody, J N ^a   Hall, J ^a   Cowell, C T ^a   Ault, J ^a   Kozlowski, K ^a   Sillence, David O ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Ectopic ossification; Inter osseous membrane; Osteogenesis imperfecta; Osteoporosis; Pamidronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

ARTICLE; BONE DENSITY; CASE REPORT; CHILD; CLINICAL FEATURE; ELBOW DISLOCATION; FEMALE; FRACTURE; HUMAN; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PRIORITY JOURNAL; REMISSION;

ANTI-INFLAMMATORY AGENTS; CHILD; DIPHOSPHONATES; FEMALE; HUMANS; OSTEOGENESIS IMPERFECTA; TREATMENT OUTCOME;

EID: 16444371252     PISSN: 10344810     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2005.00567.x     Document Type: Article

References (23)

1. Sillence DO, Senn AS, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J. Med. Genet. 1979; 16: 101-16.
2. Hall CM. International nosology and classification of constitutional disorders of bone. Am. J. Med. Genet. 2002; 113: 65-77.
3. Glorieux FH, Rauch F, Plotkin H et al. Type V Osteogenesis Imperfecta: a new form of brittle bone disease. J. Bone Miner. Res. 2000; 15: 1650-8.
4. Jones SJ, Glorieux FH, Travers R, Boyde A. The Microscopic structure of bone in normal children and patients with Osteogenesis Imperfecta: a survey using backscattered electron imaging. Calcif. Tissue Int. 1999; 64: 8-17.
5. Hamill PV, Drizd TA, Johnson CL, Reed RB, Roche AL. NCHS growth curves for children from birth to 18 years: United States. Vital Health Stat. 1977; 11: 1-74.
6. Khosla S, Kleerokoper M. Biochemical markers of bone turnover. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 4th edn. Philadelphia: Lippincott. Williams & Wilkins, 1999; 128-34.
7. Sillence DO. Craniocervical abnormalities in Osteogenesis Imperfecta. Genetic and molecular correlation. Pediatr. Radiol. 1994; 24: 427-30.
8. Verge C, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M. Effects of therapy in X-Linked Hypophosphataemic Rickets. N. Engl. J. Med. 1991; 325: 1843-8.
9. Lu PW, Briody J, Ogle G et al. Bone mineral density of total body, spine and femoral neck in children and young adults. Cross-sectional and longitudinal study. J. Bone Miner. Res. 1994; 9: 1451-7.
10. Paterson CR, McAllion S, Miller R. Osteogenesis Imperfecta with dominant inheritance and normal sclerae. J. Bone Joint Surg. Br. 1983; 65B: 35-9.
11. Smith R, Francis MJO, Houghton GR. The Brittle Bone Syndrome. Osteogenesis Imperfecta. London: Butterworths. 1983.
12. Boyde A, Travers R, Glorieux FH, Jones SJ. The mineralization density of iliac crest bone from children with Osteogenesis Imperfecta. Calcif. Tissue Int. 1999; 64: 185-90.
13. Bauze RJ, Smith R, Francis MJ. A new look at Osteogenesis imperfecta. A clinical, radiological and biochemical study of 42 patients. J. Bone Joint Surg. Br. 1975: 57B: 2-12.
14. Kozlowski K, Bittner K. Unclassified demineralizing bone in an 8 years old girl (report of a case). Australas. Radiol. 1981; 25: 76-80.
15. Sillence DO, Morley K, Ault JE. Clinical management of Osteogenesis Imperfecta. Connect. Tissue Res. 1995; 31: 15-21.
16. Langman CB. Improvement of bone in patients with Osteogenesis imperfecta treated with pamidronate-lessons from biochemistry. J. Clin. Endocrinol. Metab. 2003; 88: 984-5.
17. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J. Clin. Endocrinol. Metab. 2003; 88: 986-92.
18. Shoemaker LR. The expanding role of bisphosphonates in children. J. Pediatr. 1999; 134: 264-7.
19. Åström E, Söderhäll S. Beneficial effect of bisphosphonate during 5 years of treatment of severe Osteogenesis imperfecta. Acta. Paediatr. 1998; 87: 64-8.
20. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe Osteogenesis imperfecta. N. Engl. J. Med. 1998; 339: 947-52.
21. Batch JJ, Couper JJ, Rodda C, Cowell CT, Zacharin M. Position Paper. Use of bisphosphonate therapy for osteoporosis in childhood and adolescence. J. Paediatr. Child Health 2003; 39: 88-92.
22. Marini JC. Do bisphosphonates make children's bones better or brittle? N. Engl. J. Med. 2003; 349: 423-6.
23. The WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization Team Report Series 1994; 843: 1-129.